Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Seattle Genetics, Inc. (SGEN)

« Back to company index

SGEN Chatter Timeline

Stock Ticker for SGEN

Most Active Tweeters for SGEN

UserTweets
@whatsonthorold2 8
@bibeypost_stock 7
@AmericanBanking 6
@TranscriptDaily 5
@TheMarketsDaily 5

Recent Tweets for SGEN

YuZhu4 @YuZhu4
RT @brendan_49: $UMRX platform most directly threatens antibody-drug-conjugates which is probably by $SGEN is collaborating with them. Swap…
July 18th 2018, 3:07pm
brendan_49 @brendan_49
$SGEN's adcetris targets CD30 which is expressed on activated T-cells (and B cells), and so you can not manufacture… https://t.co/OD1CvHFK65
July 18th 2018, 3:07pm
brendan_49 @brendan_49
$UMRX platform most directly threatens antibody-drug-conjugates which is probably by $SGEN is collaborating with th… https://t.co/gq8fGcRoOm
July 18th 2018, 2:07pm
SkewViews @SkewViews
@bibeypost_stock Please repost or email anything you may know about $SGEN including earnings, insider/fund positio… https://t.co/Xl5mD1oA4J
July 18th 2018, 11:07am
TheMarketsDaily @TheMarketsDaily
Seattle Genetics $SGEN Lowered to “Hold” at BidaskClub https://t.co/NVoj2ZOoWO
July 18th 2018, 7:07am
MareaInformativ @MareaInformativ
Seattle Genetics $SGEN to Release Quarterly Earnings on Wednesday https://t.co/gXMMW6ZLsR
July 18th 2018, 6:07am
EnterpriseLeade @EnterpriseLeade
Seattle Genetics $SGEN to Release Quarterly Earnings on Wednesday https://t.co/2tqikW9U3r
July 18th 2018, 6:07am
dispatchtribune @dispatchtribune
Seattle Genetics $SGEN to Release Quarterly Earnings on Wednesday https://t.co/TmmObhFb59
July 18th 2018, 3:07am
mmahotstuff1 @mmahotstuff1
Could Seattle Genetics, Inc. $SGEN Go Down After Touching 52-Week High? - https://t.co/fExtSZxj4G
July 17th 2018, 11:07am
whatsonthorold2 @whatsonthorold2
Could Seattle Genetics, Inc. $SGEN Change Direction After Achieving 52-Week High? - https://t.co/JzwTZwVV6K
July 17th 2018, 11:07am
SwingTradeBot @SwingTradeBot
Recent $SGEN technical alerts: MACD Bearish Signal Line Cross plus 8 more alerts... https://t.co/zxmnHOoTeJ
July 17th 2018, 10:07am
MarketCurrents @MarketCurrents
Seattle Genetics down 1% on suspension of brentuximab vedotin study https://t.co/sq2LLt22cQ $SGEN
July 17th 2018, 10:07am
AlertTrade @AlertTrade
VOLUME RADAR ALERT: $SGEN SEATTLE GENETICS ? TradeIdeas via https://t.co/VS8RO1bzXJ to Free Trading Room
July 17th 2018, 10:07am
ScroogeCap @ScroogeCap
Looking at $SGEN pipeline, this NCT01771107 suspension (Brentuximab Vedotin in Lymphoma) seems rather important. https://t.co/npNplxuq4p
July 17th 2018, 9:07am
BioWino @BioWino
$sgen at all time highs.. and a safety issue pops up.
July 17th 2018, 9:07am
SWIMKILLS @SWIMKILLS
$SGEN negative FDA stops Brentuximab cancer trial, issues warning letter
July 17th 2018, 9:07am
Jcaptrading @Jcaptrading
$SGEN so we are back to scan of increase volume negative.
July 17th 2018, 2:07am
bibeypost_stock @bibeypost_stock
Seattle Genetics, Inc. $SGEN EPS Estimated At $-0.34 - https://t.co/F5oedXk8L4
July 16th 2018, 8:07pm
mmahotstuff1 @mmahotstuff1
$-0.34 EPS Expected for Seattle Genetics, Inc. $SGEN - https://t.co/Jls9g6LGrn
July 16th 2018, 8:07pm
whatsonthorold2 @whatsonthorold2
Analysts See $-0.34 EPS for Seattle Genetics, Inc. $SGEN - https://t.co/9w2BPMlTzL
July 16th 2018, 8:07pm
OlympiaReport @OlympiaReport
Seattle Genetics $SGEN Stock Rating Reaffirmed by HC Wainwright https://t.co/2f6LnAGXNr
July 16th 2018, 8:07am
ledgerzette @ledgerzette
Seattle Genetics $SGEN Stock Rating Reaffirmed by HC Wainwright https://t.co/YELH6ufnKt
July 16th 2018, 5:07am
the_chart_life @the_chart_life
$SGEN Seattle Genetics ...On the Watch List. Looking for a move above resistance. https://t.co/PKh7HebA0P
July 15th 2018, 10:07pm
bibeypost_stock @bibeypost_stock
After Making 52-Week High, Is Seattle Genetics, Inc. $SGEN's Near-Term Analysis Positive? - https://t.co/pQrQIjxfgN
July 15th 2018, 12:07pm
reurope_stock @reurope_stock
Seattle Genetics, Inc. $SGEN Stock Price Hits 52-Week High Today https://t.co/t7XQM39YXs
July 15th 2018, 12:07pm
mmahotstuff1 @mmahotstuff1
A Reversal for Seattle Genetics, Inc. $SGEN Is Not Near. The Stock Reaches 52-Week High Today - https://t.co/DdeRzkkk3w
July 15th 2018, 12:07pm
whatsonthorold2 @whatsonthorold2
Is Buying Seattle Genetics, Inc. $SGEN Here a Winning Strategy? - https://t.co/hft32BfRIT
July 15th 2018, 12:07pm
TheMarketsDaily @TheMarketsDaily
Seattle Genetics $SGEN Earns Buy Rating from HC Wainwright https://t.co/4zElK9wNCW
July 15th 2018, 11:07am
TheMarketsDaily @TheMarketsDaily
Analyzing Seattle Genetics $SGEN and Adverum Biotechnologies $ADVM https://t.co/nckPhqjgF1
July 15th 2018, 10:07am
dailypoliticaln @dailypoliticaln
Adverum Biotechnologies $ADVM versus Seattle Genetics $SGEN Financial Survey https://t.co/V9Groa5aPc
July 15th 2018, 10:07am
dispatchtribune @dispatchtribune
Seattle Genetics’ $SGEN Buy Rating Reiterated at HC Wainwright https://t.co/AwmM22VLd6
July 15th 2018, 9:07am
TranscriptDaily @TranscriptDaily
Seattle Genetics $SGEN Given Buy Rating at HC Wainwright https://t.co/E9BChNuqzD
July 15th 2018, 8:07am
OlympiaReport @OlympiaReport
Seattle Genetics, Inc. $SGEN Insider Sells $1,300,726.24 in Stock https://t.co/5Y4ntmQXTs
July 14th 2018, 11:07pm
ResearchPool @ResearchPool
$SGEN #Seattle Genetics Inc., Continued expansion of Adcetris indications and pipeline progress support a positive… https://t.co/h6vgQQhyTm
July 13th 2018, 4:07pm
bibeypost_stock @bibeypost_stock
What Next for Seattle Genetics, Inc. $SGEN Stock After Reaching 52-Week High? - https://t.co/gcR1m3qBpG
July 13th 2018, 2:07pm
mmahotstuff1 @mmahotstuff1
What's Next for Seattle Genetics, Inc. $SGEN After Touching 52-Week High? - https://t.co/EHo9CxgKgz
July 13th 2018, 2:07pm
whatsonthorold2 @whatsonthorold2
After Achieving 52-Week High, Is Seattle Genetics, Inc. $SGEN's Near-Term Analysis Positive? - https://t.co/21NFpXslmy
July 13th 2018, 2:07pm
DesertDweller93 @DesertDweller93
$sgen is sure to continue higher as I just took some off the table. Figured I would be like Clay and sell a portion… https://t.co/nrtEt07wdj
July 13th 2018, 12:07pm
TopStockAlerts1 @TopStockAlerts1
Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering $SLS $SGEN… https://t.co/uGPV2wmiL6
July 13th 2018, 9:07am
TranscriptDaily @TranscriptDaily
Seattle Genetics, Inc. $SGEN Insider Clay B. Siegall Sells 18,832 Shares https://t.co/Oq66OfHNoC
July 13th 2018, 4:07am
WeekHerald @WeekHerald
Seattle Genetics $SGEN Reaches New 52-Week High at $70.51 https://t.co/VeswWuaj3n
July 12th 2018, 4:07pm
OlympiaReport @OlympiaReport
Seattle Genetics $SGEN Sets New 12-Month High at $70.51 https://t.co/wHyXQMU1Rf
July 12th 2018, 4:07pm
MaisaCorp @MaisaCorp
$SGEN Doses First Patient in Tisotumab Vedotin Study For Multiple Solid Tumors
July 12th 2018, 3:07pm
TranscriptDaily @TranscriptDaily
-$0.34 EPS Expected for Seattle Genetics, Inc. $SGEN This Quarter https://t.co/tCaCCW271B
July 12th 2018, 1:07pm
TheMarketsDaily @TheMarketsDaily
Seattle Genetics, Inc. $SGEN Expected to Post Quarterly Sales of $143.32 Million https://t.co/araZUq3Tn6
July 12th 2018, 1:07pm
dakotafinancial @dakotafinancial
Seattle Genetics, Inc. $SGEN Insider Clay B. Siegall Sells 18,832 Shares https://t.co/StdQ0OiS6D
July 12th 2018, 12:07pm
MareaInformativ @MareaInformativ
Seattle Genetics, Inc. $SGEN Insider Clay B. Siegall Sells 18,832 Shares https://t.co/FirVy5MtVF
July 12th 2018, 9:07am
MarketCurrents @MarketCurrents
Mid-stage study underway for Seattle Genetics' tisotumab vedotin in solid tumors; shares up 1% p... https://t.co/i4tl0fKp7I #premarket $SGEN
July 12th 2018, 8:07am
JSTOCKBROKERS @JSTOCKBROKERS
RT @odibro: $SGEN First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors https://t.co/kCE6…
July 12th 2018, 8:07am
odibro @odibro
$SGEN First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors https://t.co/kCE6uUAAkR
July 12th 2018, 8:07am

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2018. All rights reserved.